Format

Send to

Choose Destination
Ther Clin Risk Manag. 2017 Dec 11;13:1555-1562. doi: 10.2147/TCRM.S144121. eCollection 2017.

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.

Author information

1
Department of Food and Drug, University of Parma, Parma.
2
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua.
3
Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan.
4
Department of Neurosciences.
5
Hypertension Research Center, Federico II University, Naples, Italy.

Abstract

Background:

A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by reducing proprotein convertase subtilisin kexin type 9 (PCSK9), independently of lipoprotein concentrations.

Aim:

We aimed to evaluate the effect of an innovative nutraceutical (NUT) combination containing red yeast rice (monacolin K 3.3 mg), berberine 531.25 mg and leaf extract of Morus alba 200 mg (LopiGLIK®), on HDL-CEC, serum CLC and on circulating PCSK9 levels.

Materials and methods:

Twenty three dyslipidemic subjects were treated for 4 weeks with the above NUT combination. HDL-CEC was measured using specific cell-based radioisotopic assays; serum CLC and PCSK9 concentrations were measured fluorimetrically and by enzyme-linked immunosorbent assay, respectively.

Results:

The NUT combination significantly reduced plasma level of the total cholesterol and low-density lipoprotein cholesterol (-9.8% and -12.6%, respectively). Despite no changes in HDL-cholesterol, the NUT combination improved total HDL-CEC in 83% of the patients, by an average of 16%, as a consequence of the increase mainly of the ATP-binding cassette A1-mediated CEC (+28.5%). The NUT combination significantly reduced serum CLC (-11.4%) while it did not change PCSK9 plasma levels (312.9±69.4 ng/mL vs 334.8±103.5 mg/L, before and after treatment, respectively).

Conclusion:

The present NUT combination improves the serum lipoprotein functional profile providing complementary beneficial effects, without any detrimental increase of PCSK9 plasma levels.

KEYWORDS:

HDL; Morus alba; PCSK9; berberine; cholesterol efflux capacity; macrophage; monacolin K; nutraceutical

Conflict of interest statement

Disclosure Franco Bernini received support for this study from Akademy Pharma Srl (Milano, Italy). The other authors report no conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center